Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC + Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer.

Authors:

Abstract
Background: Since pathological complete responses (pCR) might be a surrogate for effective eradication of micrometastatic disease leading possibly to prolonged overall survival in primary breast cancer, neoadjuvant treatment of early breast cancer aims at achieving high rates of pCR.Methods: Primary aim of ABCSG-24 is to evaluate the influence of 6 cycles of EDC±T (experimental group) as compared to 6 cycles of ED±T (control group) on the rate of pCR at the time of surgery. 536 patients (pts) (268 pts/group, 5% dropout rate for 510 eligible pts, power=83%,p: Neoadjuvant EDC in early breast cancer results in a significantly higher pCR rate than ED. ED/EDC + T leads to a non-significant higher rate of pCR than ED/EDC alone which might be due to a higher observed rate of pCR with ED/EDC alone than the expected. ED/EDC+/-T are feasible for outpatient use but C associated toxicity must be monitored closely and dose reduction rules must be observed. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 1081.